Literature Search
1. Your Research Question
Hypertention ,does the use of angiotension converting enzyme inhibitors compared to calcium channel
blockers lead to a greater reduction in blood pressure.
Plan your SEARCH
2.
PICO
Patient
(Population) Hypertension
Intervention
angiotensin
(Exposure)
converting
enzyme
Synony
ms
Hyperte
nsion
High
blood
pressure
Elevate
d blood
pressure
Medical Subheading (MeSH)
Angiote
nsin
converti
ng
enzyme
Search: (((angiotensin converting enzyme) OR (angiotensinconverting enzyme)) OR (peptidyl-dipeptidase A)) AND
("Angiotensin-Converting Enzyme Inhibitors"[Mesh] OR
"Angiotensin-Converting Enzyme Inhibitors" [Pharmacological
Action])
("peptidyl dipeptidase a"[MeSH Terms] OR "peptidyl dipeptidase
a"[All Fields] OR ("angiotensin"[All Fields] AND "converting"[All
Fields] AND "enzyme"[All Fields]) OR "angiotensin converting
enzyme"[All Fields] OR ("peptidyl dipeptidase a"[MeSH Terms] OR
"peptidyl dipeptidase a"[All Fields] OR ("angiotensin"[All Fields]
angiote
nsinconverti
ng
Search: (((hypertension) OR (high blood pressure)) OR
(elevated blood pressure)) AND ("Hypertension"[Mesh] OR
"Intra-Abdominal Hypertension"[Mesh] OR "Intracranial
Hypertension"[Mesh] OR "Hypertension, Renal"[Mesh] OR
"Hypertension, Pulmonary"[Mesh] OR "Hypertension,
Malignant"[Mesh])
("hypertense"[All Fields] OR "Hypertension"[MeSH Terms] OR
"Hypertension"[All Fields] OR "hypertension s"[All Fields] OR
"hypertensions"[All Fields] OR "hypertensive"[All Fields] OR
"hypertensive s"[All Fields] OR "hypertensives"[All Fields] OR
("Hypertension"[MeSH Terms] OR "Hypertension"[All Fields] OR
("high"[All Fields] AND "blood"[All Fields] AND "pressure"[All
Fields]) OR "high blood pressure"[All Fields]) OR
("Hypertension"[MeSH Terms] OR "Hypertension"[All Fields] OR
("elevated"[All Fields] AND "blood"[All Fields] AND "pressure"[All
Fields]) OR "elevated blood pressure"[All Fields])) AND
("Hypertension"[MeSH Terms] OR "Intra-Abdominal
Hypertension"[MeSH Terms] OR "Intracranial Hypertension"[MeSH
Terms] OR "hypertension, renal"[MeSH Terms] OR "hypertension,
pulmonary"[MeSH Terms] OR "hypertension, malignant"[MeSH
Terms])
Translations
hypertension: "hypertense"[All Fields] OR "hypertension"[MeSH
Terms] OR "hypertension"[All Fields] OR "hypertension's"[All
Fields] OR "hypertensions"[All Fields] OR "hypertensive"[All Fields]
OR "hypertensive's"[All Fields] OR "hypertensives"[All Fields]
high blood pressure: "hypertension"[MeSH Terms] OR
"hypertension"[All Fields] OR ("high"[All Fields] AND "blood"[All
Fields] AND "pressure"[All Fields]) OR "high blood pressure"[All
Fields]
elevated blood pressure: "hypertension"[MeSH Terms] OR
"hypertension"[All Fields] OR ("elevated"[All Fields] AND
"blood"[All Fields] AND "pressure"[All Fields]) OR "elevated blood
pressure"[All Fields]
Comparison
enzyme
peptidyl
dipeptid
ase A
AND "converting"[All Fields] AND "enzyme"[All Fields]) OR
"angiotensin converting enzyme"[All Fields]) OR ("peptidyl
dipeptidase a"[MeSH Terms] OR "peptidyl dipeptidase a"[All
Fields] OR "peptidyl dipeptidase a"[All Fields])) AND ("AngiotensinConverting Enzyme Inhibitors"[MeSH Terms] OR "AngiotensinConverting Enzyme Inhibitors"[Pharmacological Action])
Translations
angiotensin converting enzyme: "peptidyl-dipeptidase a"[MeSH
Terms] OR "peptidyl-dipeptidase a"[All Fields] OR
("angiotensin"[All Fields] AND "converting"[All Fields] AND
"enzyme"[All Fields]) OR "angiotensin converting enzyme"[All
Fields]
angiotensin-converting enzyme: "peptidyl-dipeptidase a"[MeSH
Terms] OR "peptidyl-dipeptidase a"[All Fields] OR
("angiotensin"[All Fields] AND "converting"[All Fields] AND
"enzyme"[All Fields]) OR "angiotensin converting enzyme"[All
Fields]
peptidyl-dipeptidase A: "peptidyl-dipeptidase a"[MeSH Terms]
OR "peptidyl-dipeptidase a"[All Fields] OR "peptidyl dipeptidase
a"[All Fields]
calcium Search: (((calcium channel blockers) OR (calcium-channel
calcium channel channel blockers)) OR (calcium antagonists)) AND ("Calcium Channel
blockers
blockers Blockers"[Mesh] OR "Calcium Channel Blockers"
[Pharmacological Action])
calcium ("Calcium Channel Blockers"[Pharmacological Action] OR "Calcium
Channel Blockers"[MeSH Terms] OR ("calcium"[All Fields] AND
channel "channel"[All Fields] AND "blockers"[All Fields]) OR "Calcium
blockers Channel Blockers"[All Fields] OR ("Calcium Channel
Blockers"[Pharmacological Action] OR "Calcium Channel
calcium Blockers"[MeSH Terms] OR ("calcium"[All Fields] AND "channel"[All
antagon Fields] AND "blockers"[All Fields]) OR "Calcium Channel
ists
Blockers"[All Fields]) OR ("Calcium Channel
Blockers"[Pharmacological Action] OR "Calcium Channel
Blockers"[MeSH Terms] OR ("calcium"[All Fields] AND "channel"[All
Fields] AND "blockers"[All Fields]) OR "Calcium Channel
Blockers"[All Fields] OR ("calcium"[All Fields] AND "antagonists"[All
Fields]) OR "calcium antagonists"[All Fields])) AND ("Calcium
Channel Blockers"[MeSH Terms] OR "Calcium Channel
Blockers"[Pharmacological Action])
Translations
calcium channel blockers: "calcium channel
blockers"[Pharmacological Action] OR "calcium channel
blockers"[MeSH Terms] OR ("calcium"[All Fields] AND "channel"[All
Fields] AND "blockers"[All Fields]) OR "calcium channel
blockers"[All Fields]
calcium-channel blockers: "calcium channel
Outcome
blockers"[Pharmacological Action] OR "calcium channel
blockers"[MeSH Terms] OR ("calcium"[All Fields] AND "channel"[All
Fields] AND "blockers"[All Fields]) OR "calcium channel
blockers"[All Fields]
calcium antagonists: "calcium channel blockers"[Pharmacological
Action] OR "calcium channel blockers"[MeSH Terms] OR
("calcium"[All Fields] AND "channel"[All Fields] AND "blockers"[All
Fields]) OR "calcium channel blockers"[All Fields] OR ("calcium"[All
Fields] AND "antagonists"[All Fields]) OR "calcium antagonists"[All
Fields]
Antihyp
antihypertensive ertensiv
e
Antihyperte
nsive
Reduce
d blood
pressure
Search: (((antihypertensive) OR (anti-hypertensive)) OR
(reduced blood pressure)) AND ("Antihypertensive
Agents"[Mesh] OR "Antihypertensive Agents"
[Pharmacological Action])
("antihypertension"[All Fields] OR "Antihypertensive
Agents"[Pharmacological Action] OR "Antihypertensive
Agents"[MeSH Terms] OR ("antihypertensive"[All Fields] AND
"agents"[All Fields]) OR "Antihypertensive Agents"[All Fields] OR
"antihypertensive"[All Fields] OR "antihypertensives"[All Fields] OR
("Antihypertensive Agents"[Pharmacological Action] OR
"Antihypertensive Agents"[MeSH Terms] OR ("antihypertensive"[All
Fields] AND "agents"[All Fields]) OR "Antihypertensive Agents"[All
Fields] OR ("anti"[All Fields] AND "hypertensive"[All Fields]) OR
"anti hypertensive"[All Fields]) OR (("reduce"[All Fields] OR
"reduced"[All Fields] OR "reduces"[All Fields] OR "reducing"[All
Fields]) AND ("blood pressure"[MeSH Terms] OR ("blood"[All
Fields] AND "pressure"[All Fields]) OR "blood pressure"[All Fields]
OR "blood pressure determination"[MeSH Terms] OR ("blood"[All
Fields] AND "pressure"[All Fields] AND "determination"[All Fields])
OR "blood pressure determination"[All Fields] OR "arterial
pressure"[MeSH Terms] OR ("arterial"[All Fields] AND
"pressure"[All Fields]) OR "arterial pressure"[All Fields]))) AND
("Antihypertensive Agents"[MeSH Terms] OR "Antihypertensive
Agents"[Pharmacological Action])
Translations
antihypertensive: "antihypertension"[All Fields] OR
"antihypertensive agents"[Pharmacological Action] OR
"antihypertensive agents"[MeSH Terms] OR ("antihypertensive"[All
Fields] AND "agents"[All Fields]) OR "antihypertensive agents"[All
Fields] OR "antihypertensive"[All Fields] OR "antihypertensives"[All
Fields]
anti-hypertensive: "antihypertensive agents"[Pharmacological
Action] OR "antihypertensive agents"[MeSH Terms] OR
("antihypertensive"[All Fields] AND "agents"[All Fields]) OR
"antihypertensive agents"[All Fields] OR ("anti"[All Fields] AND
"hypertensive"[All Fields]) OR "anti hypertensive"[All Fields]
reduced: "reduce"[All Fields] OR "reduced"[All Fields] OR
"reduces"[All Fields] OR "reducing"[All Fields]
blood pressure: "blood pressure"[MeSH Terms] OR ("blood"[All
Fields] AND "pressure"[All Fields]) OR "blood pressure"[All Fields]
OR "blood pressure determination"[MeSH Terms] OR ("blood"[All
Fields] AND "pressure"[All Fields] AND "determination"[All Fields])
OR "blood pressure determination"[All Fields] OR "arterial
pressure"[MeSH Terms] OR ("arterial"[All Fields] AND
"pressure"[All Fields]) OR "arterial pressure"[All Fields]
Other considerations
Where do you plan to
search
What types of studies are you
planning to include
(other data bases)
pubmed
PEDro
Cochrane library
Medline
Sci Hub
Clinical Trial
Meta-Analysis
systematic Review
Randomized Controlled Trial
Are there any inclusion / exclusion
criteria that could be applied as
search limits, e.g. population
demographics (such as age,
gender, ethnicity)?
Age
Body composition
Gender female
ethnicity
3. Snapshot of “Search history”
Replace this picture with your one
4. Add the “ Summary text”
Once you finish selection, Go to save and select ‘selection’, ‘summary text’ and create the file.
Paste the content here
1: Sundström J, Lind L, Nowrouzi S, Hagström E, Held C, Lytsy P, Neal B,
Marttala K, Östlund O. Heterogeneity in Blood Pressure Response to 4
Antihypertensive Drugs: A Randomized Clinical Trial. JAMA. 2023 Apr
11;329(14):1160-1169. doi: 10.1001/jama.2023.3322. PMID: 37039792; PMCID:
PMC10091169.
2: Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and
psoriasis: A systematic review, meta- and network meta-analysis. Br J Clin
Pharmacol. 2022 Mar;88(3):933-941. doi: 10.1111/bcp.15060. Epub 2021 Oct 5.
PMID: 34611920.
3: Xie M, Tang T, Liang H. Efficacy of single-pill combination in uncontrolled
essential hypertension: A systematic review and network meta-analysis. Clin
Cardiol. 2023 Aug;46(8):886-898. doi: 10.1002/clc.24082. Epub 2023 Jul 11. PMID:
37432701; PMCID: PMC10436803.
4: Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, Smith Byrne K,
Sundström J, Teo K, Davis BR, Chalmers J, Pepine CJ, Dehghan A, Bennett DA,
Smith GD, Rahimi K; Blood Pressure Lowering Treatment Trialists’ Collaboration.
Blood pressure lowering and risk of new-onset type 2 diabetes: an individual
participant data meta-analysis. Lancet. 2021 Nov 13;398(10313):1803-1810. doi:
10.1016/S0140-6736(21)01920-6. PMID: 34774144; PMCID: PMC8585669.
5: Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke
J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and
safety of first-line antihypertensive drug classes: a systematic, multinational,
large-scale analysis. Lancet. 2019 Nov 16;394(10211):1816-1826. doi:
10.1016/S0140-6736(19)32317-7. Epub 2019 Oct 24. PMID: 31668726; PMCID:
PMC6924620.
6: Naci H, Salcher-Konrad M, Dias S, Blum MR, Sahoo SA, Nunan D, Ioannidis JPA.
How does exercise treatment compare with antihypertensive medications? A network
meta-analysis of 391 randomised controlled trials assessing exercise and
medication effects on systolic blood pressure. Br J Sports Med. 2019
Jul;53(14):859-869. doi: 10.1136/bjsports-2018-099921. Epub 2018 Dec 18. PMID:
30563873.
7: Qi J, An R, Bhatti P, Spinelli JJ, Murphy RA. Anti-hypertensive medications
and risk of colorectal cancer: a systematic review and meta-analysis. Cancer
Causes Control. 2022 Jun;33(6):801-812. doi: 10.1007/s10552-022-01570-1. Epub
2022 Mar 21. PMID: 35314908.
8: den Brok MGHE, van Dalen JW, Abdulrahman H, Larson EB, van Middelaar T, van
Gool WA, van Charante EPM, Richard E. Antihypertensive Medication Classes and
the Risk of Dementia: A Systematic Review and Network Meta-Analysis. J Am Med
Dir Assoc. 2021 Jul;22(7):1386-1395.e15. doi: 10.1016/j.jamda.2020.12.019. Epub
2021 Jan 16. PMID: 33460618.
9: Fishel Bartal M, Blackwell SC, Pedroza C, Lawal D, Amro F, Samuel J, Chauhan
SP, Sibai BM. Oral combined hydrochlorothiazide and lisinopril vs nifedipine for
postpartum hypertension: a comparative-effectiveness pilot randomized controlled
trial. Am J Obstet Gynecol. 2023 May;228(5):571.e1-571.e10. doi:
10.1016/j.ajog.2023.01.015. Epub 2023 Feb 12. PMID: 36787814.
10: Najmeddin F, Solhjoo M, Ashraf H, Salehi M, Rasooli F, Ghoghaei M, Soleimani
A, Bahreini M. Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early
Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical
Trial. Am J Hypertens. 2021 Nov 20;34(11):1217-1226. doi: 10.1093/ajh/hpab111.
PMID: 34265044; PMCID: PMC8344947.
11: Hu N, Ji H. Medications on hypertension, hyperlipidemia, diabetes, and risk
of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol
Sci. 2022 Sep;43(9):5189-5199. doi: 10.1007/s10072-022-06131-7. Epub 2022 May
26. PMID: 35616813.
12: Salem M, Sallam AM, Abdel-Aleem E, El-Mesallamy HO. Effect of Lisinopril and
Verapamil on Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients
with Nephropathy: A Randomized Trial. Horm Metab Res. 2021 Jul;53(7):470-477.
doi: 10.1055/a-1517-6643. Epub 2021 Jul 19. PMID: 34282598.
13: Yoselevsky EM, Seely EW, Celi AC, Robinson JN, McElrath TF. A randomized
controlled trial comparing the efficacy of nifedipine and enalapril in the
postpartum period. Am J Obstet Gynecol MFM. 2023 Dec;5(12):101178. doi:
10.1016/j.ajogmf.2023.101178. Epub 2023 Oct 6. PMID: 37806651.
14: Bao H, Huang X, Li P, Sheng C, Zhang J, Wang Z, Song D, Hu L, Ding C, Cheng
Z, Yao C, Chen G, Cui Y, Qin X, Tang G, Wang X, Huo Y, Cheng X, Wang J. Combined
use of amlodipine and folic acid are significantly more efficacious than
amlodipine alone in lowering plasma homocysteine and blood pressure among
hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A
multicenter, randomized, double-blind, parallel-controlled clinical trial. J
Clin Hypertens (Greenwich). 2023 Aug;25(8):689-699. doi: 10.1111/jch.14697. Epub
2023 Jul 11. PMID: 37433173; PMCID: PMC10423753.
15: Ma H, Jiang H, Feng J, Gan Y. Angiotensin Receptor Blocker and Calcium
Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with
Hypertension and Atrial Fibrillation: A Meta-analysis. Cardiovasc Ther. 2021 May
17;2021:6628469. doi: 10.1155/2021/6628469. PMID: 34104205; PMCID: PMC8149258.
16: Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E,
Giannakoulas G. Effects of Major Antihypertensive Drug Classes on Erectile
Function: a Network Meta-analysis. Cardiovasc Drugs Ther. 2022
Oct;36(5):903-914. doi: 10.1007/s10557-021-07197-9. Epub 2021 May 4. PMID:
33945044.
17: Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC,
Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz
LA, Rehman SU, Roumie CL, Tamariz L, King JB. Antihypertensive Medication
Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension.
2023 Mar;80(3):590-597. doi: 10.1161/HYPERTENSIONAHA.122.20373. Epub 2022 Dec
15. PMID: 36519451; PMCID: PMC9931643.
18: Peng X, Peng DF, Tang SY. Effect of diltiazem on exercise tolerance in
patients with stable coronary artery disease and hypertension. J Physiol
Pharmacol. 2021 Aug;72(4). doi: 10.26402/jpp.2021.4.07. Epub 2021 Dec 31. PMID:
34987129.
19: Azoulay L, St-Jean A, Dahl M, Quail J, Aibibula W, Brophy JM, Chan AW,
Bresee L, Carney G, Eltonsy S, Tamim H, Paterson JM, Platt RW; Canadian Network
for Observational Drug Effect Studies (CNODES) Investigators.
Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A
multisite population-based cohort study. J Am Acad Dermatol. 2023
Aug;89(2):243-253. doi: 10.1016/j.jaad.2023.04.035. Epub 2023 Apr 25. PMID:
37105517.
20: Honda A, Tahara N, Tahara A, Bekki M, Maeda-Ogata S, Sugiyama Y, Igata S,
Nishino Y, Matsui T, Kurata S, Abe T, Yamagishi SI, Fukumoto Y. Effects of
olmesartan and amlodipine on blood pressure, endothelial function, and vascular
inflammation. J Nucl Cardiol. 2023 Aug;30(4):1613-1626. doi:
10.1007/s12350-023-03200-y. Epub 2023 Feb 3. PMID: 36737518.
21: Hu Y, Liang L, Liu S, Kung JY, Banh HL. Angiotensin-converting enzyme
inhibitor induced cough compared with placebo, and other antihypertensives: A
systematic review, and network meta-analysis. J Clin Hypertens (Greenwich). 2023
Aug;25(8):661-688. doi: 10.1111/jch.14695. Epub 2023 Jul 7. PMID: 37417783;
PMCID: PMC10423763.
22: Qin L, Zhang N, Ishigami J, Miller ER 3rd, Pfister M, Moran AE, Cox E.
Dyskalemia risk associated with fixed-dose anti-hypertensive medication
combinations. J Hum Hypertens. 2022 Nov;36(11):989-995. doi:
10.1038/s41371-021-00600-w. Epub 2021 Sep 23. PMID: 34556798.
23: Guo QH, Zhu ZM, Feng YQ, Lin JX, Wang JG. Blood pressure lowering effects of
β-blockers as add-on or combination therapy: A meta-analysis of randomized
controlled trials. J Clin Hypertens (Greenwich). 2023 Mar;25(3):227-237. doi:
10.1111/jch.14616. Epub 2023 Feb 8. PMID: 36756690; PMCID: PMC9994166.
24: Langerhuizen DWG, Verweij LPE, van der Wouden JC, Kerkhoffs GMMJ, Janssen
SJ. Antihypertensive drugs demonstrate varying levels of hip fracture risk: A
systematic review and meta-analysis. Injury. 2022 Mar;53(3):1098-1107. doi:
10.1016/j.injury.2021.09.036. Epub 2021 Sep 28. PMID: 34627629.
25: Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M,
Chalmers J, Teo KK, Pepine CJ, Davis BR, Kjeldsen S, Sundström J, Rahimi K;
Blood Pressure Lowering Treatment Trialists' Collaboration. Antihypertensive
treatment and risk of cancer: an individual participant data meta-analysis.
Lancet Oncol. 2021 Apr;22(4):558-570. doi: 10.1016/S1470-2045(21)00033-4. PMID:
33794209; PMCID: PMC8024901.
26: Ileri C, Dogan Z, Ozben B, Bircan L, Acet A, Sen T. The Impact of Timing of
Fixed Dose Triple Antihypertensive Combinations on Ambulatory Blood Pressure
Monitoring Parameters. Clin Exp Hypertens. 2023 Dec 31;45(1):2224941. doi:
10.1080/10641963.2023.2224941. PMID: 37337964.
27: Ren L, Yu S, Xu W, Overton JL, Chiamvimonvat N, Thai PN. Lack of association
of antihypertensive drugs with the risk and severity of COVID-19: A metaanalysis. J Cardiol. 2021 May;77(5):482-491. doi: 10.1016/j.jjcc.2020.10.015.
Epub 2020 Nov 2. PMID: 33168337; PMCID: PMC7605745.
28: Mazza A, Townsend DM, Schiavon L, Torin G, Lenti S, Rossetti C, Rigatelli G,
Rubello D. Long-term effect of the perindopril/indapamide/amlodipine single-pill
combination on left ventricular hypertrophy in outpatient hypertensive subjects.
Biomed Pharmacother. 2019 Dec;120:109539. doi: 10.1016/j.biopha.2019.109539.
Epub 2019 Oct 15. PMID: 31627089; PMCID: PMC7104809.
29: Goldstein ED, Wolcott Z, Garg G, Navarro K, Delic A, Yaghi S, Sederholm B,
Prabhakaran S, Wong KH, McLean K, de Havenon AH. Effect of Antihypertensives by
Class on Cerebral Small Vessel Disease: A Post Hoc Analysis of SPRINT-MIND.
Stroke. 2022 Aug;53(8):2435-2440. doi: 10.1161/STROKEAHA.121.037997. Epub 2022
May 4. PMID: 35506388.
30: Seleme VB, Marques GL, Mendes AEM, Rotta I, Pereira M, Júnior EL, da Cunha
CLP. Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A
Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2021
Mar;21(2):165-180. doi: 10.1007/s40256-020-00422-0. PMID: 32710438.
31: Yamal JM, Martinez J, Osani MC, Du XL, Simpson LM, Davis BR. Mortality and
Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE
Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized
Clinical Trial. JAMA Netw Open. 2023 Dec 1;6(12):e2344998. doi:
10.1001/jamanetworkopen.2023.44998. PMID: 38048133; PMCID: PMC10696481.
32: Du XL, Simpson LM, Tandy BC, Bettencourt JL, Davis BR. Risk of hospitalized
and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants
receiving diuretic, ACE-inhibitor, or calcium-channel blocker. PLoS One. 2021
Nov 18;16(11):e0260107. doi: 10.1371/journal.pone.0260107. PMID: 34793552;
PMCID: PMC8601451.
33: Cho M, Choi CY, Choi YJ, Rhie SJ. Clinical outcomes of renin angiotensin
system inhibitor-based dual antihypertensive regimens in chronic kidney disease:
a network meta-analysis. Sci Rep. 2023 Apr 7;13(1):5727. doi:
10.1038/s41598-023-32266-4. PMID: 37029191; PMCID: PMC10082011.
34: Bezabih YM, Bezabih A, Alamneh E, Peterson GM, Bezabhe W. Comparison of
renin-angiotensin-aldosterone system inhibitors with other antihypertensives in
association with coronavirus disease-19 clinical outcomes. BMC Infect Dis. 2021
Jun 5;21(1):527. doi: 10.1186/s12879-021-06088-6. PMID: 34090358; PMCID:
PMC8178664.
35: Ojji DB, Cornelius V, Partington G, Francis V, Pandie S, Smythe W, Hickman
N, Barasa F, Damasceno A, Dzudie A, Jones E, Ingabire PM, Mondo C, Ogah O, Ogola
E, Sani MU, Shedul GL, Shedul G, Rayner B, Sliwa K, Poulter N; for CREOLE
Investigators. Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on
Blood Pressure Variability in Black African Patients: Secondary Analyses of the
CREOLE Trial. Hypertension. 2022 Nov;79(11):2593-2600. doi:
10.1161/HYPERTENSIONAHA.121.18333. Epub 2022 Sep 2. PMID: 36052684.
36: Nakagawa N, Sato N, Saijo Y, Morimoto H, Koyama S, Ogawa Y, Uekita K,
Maruyama J, Ohta T, Nakamura Y, Takeuchi T, Hasebe N; ASAHI-AI investigators.
Assessment of suitable antihypertensive therapies: Combination with high-dose
amlodipine/irbesartan vs triple combination with
amlodipine/irbesartan/indapamide (ASAHI-AI study). J Clin Hypertens (Greenwich).
2020 Sep;22(9):1577-1584. doi: 10.1111/jch.13977. Epub 2020 Aug 6. PMID:
32762115; PMCID: PMC8029846.
37: Poulter NR, Dolan E, Gupta AK, O'Brien E, Whitehouse A, Sever PS. Efficacy
and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril
and Amlodipine in the Management of Hypertension. Am J Cardiovasc Drugs. 2019
Jun;19(3):313-323. doi: 10.1007/s40256-018-00314-4. PMID: 30919249.
38: Barzilay JI, Lai D, Davis BR, Pressel S, Previn HE, Arnett DK. The
Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive
Medications for Incident Glucose-level Elevation. Am J Hypertens. 2019 Mar
16;32(4):343-349. doi: 10.1093/ajh/hpy199. PMID: 30590387; PMCID: PMC6420683.
39: Zhang J, Tong A, Dai Y, Niu J, Yu F, Xu F. Comparative risk of new-onset
diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network
meta-analysis. J Clin Hypertens (Greenwich). 2019 Aug;21(8):1082-1090. doi:
10.1111/jch.13598. Epub 2019 Jun 26. PMID: 31241860; PMCID: PMC8030293.
5. Write a short reflection on the process in 250 words. (What have you learned and how this will
be useful in your professional career?)
These data reveal substantial heterogeneity in blood pressure response to drug therapy for
hypertension, findings that may have implications for personalized therapy. Some study confirmed
the associations between antihypertensive drugs and psoriasis; ACE inhibitors, BBs, CCBs and
thiazide diuretics increased the risk of psoriasis. Therefore, antihypertensive drug users should be
carefully monitored for psoriasis
he effect of exercise interventions on SBP remains under-studied, especially among hypertensive
populations. Our findings confirm modest but consistent reductions in SBP in many studied
exercise interventions across all populations but individuals receiving medications generally
achieved greater reductions than those following structured exercise regimens. Assuming equally
reliable estimates, the SBP-lowering effect of exercise among hypertensive populations appears
similar to that of commonly used antihypertensive medications. Generalisability of these findings
to real-world clinical settings should be further evaluated.
His randomized triple-blind multicentric clinical trial did not show any deleterious effects of
ACEi/ARB medications in hypertensive COVID-19 patients.
Engaging in evidence based practice on PubMed for hypertension has been enlightening through
this process, I have learned the significance of critically evaluating research studies to inform
clinical decision making. Understanding the latest evidence allows for more effective and tailored
treatment approaches in the physiotherapy.it enhances my ability to provide patient cantered care,
ensuring interventions are based on the most current and reliable evidence available. This approach
fosters confidence in my practice and promote better outcome for patient. these data reveal
substantial heterogeneity in blood pressure response to drug therapy for hypertension, findings that
may have implications for personalized therapy, physiotherapy or any other medical career.